Last reviewed · How we verify
Placebo administered by Magnair — Competitive Intelligence Brief
marketed
Respiratory
Small molecule
Live · refreshed every 30 min
Target snapshot
Placebo administered by Magnair (Placebo administered by Magnair) — Sunovion Respiratory Development Inc.. Placebo produces no pharmacological effect and serves as a control comparator in clinical trials.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Placebo administered by Magnair TARGET | Placebo administered by Magnair | Sunovion Respiratory Development Inc. | marketed |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Placebo administered by Magnair CI watch — RSS
- Placebo administered by Magnair CI watch — Atom
- Placebo administered by Magnair CI watch — JSON
- Placebo administered by Magnair alone — RSS
Cite this brief
Drug Landscape (2026). Placebo administered by Magnair — Competitive Intelligence Brief. https://druglandscape.com/ci/placebo-administered-by-magnair. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab